glp 1 ra injection GLP-1 receptor agonist use linked to lower mortality in seniors with cancer, T2D Beyond the GLP-1RA weight loss

Data availability The anonymized data from the PIPD and ET dataset are available at the Science Data Bank ( and respectively)

Key Highlights: Primary endpoint met: ~1.72.0% A1C reduction at 40 weeks vs ~0.8% placebo Significant weight loss: ~1517% reduction vs ~2.5% placebo Sustained efficacy: No weight-loss plateau observed over study duration Triple mechanism: Targets GLP-1, GIP & glucagon receptors for amplified metabolic effects Convenient dosing: Once-weekly injectable therapy Why It Matters: Beyond GLP-1: Signals the shift to multi-hormone incretin therapies Dual efficacy: Combines deep A1C reduction + substantial weight loss Competitive edge: Strengthens Lillys position vs semaglutide & tirzepatide Holistic impact: Potential to improve broader cardiometabolic outcomes Key Takeaway: Retatrutide is emerging as a potential best-in-class metabolic therapy, combining powerful glucose lowering with significant weight loss

Who should avoid BPC157

In a poll where Sermo members shared their biggest concern when prescribing GLP-1 drugs, muscle loss/frailty was the third most popular answer, with 19% of votes